My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Pasithea Therapeutics Corp. - Common Stock (NQ:KTTA)

0.7101 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pasithea Therapeutics Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope ↗

October 10, 2022

People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.

Via Benzinga

Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis

October 03, 2022

By Mark Gilman, Benzinga

Via News Direct

Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis ↗

October 03, 2022

Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 31, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 30, 2022

Via Benzinga

Pasithea Therapeutics Awarded A Drug Development Research Grant ↗

July 14, 2022

-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction -- -- Provides approximately U.S. $694,000 of non-dilutive funding --

Via Benzinga

EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox ↗

August 11, 2022

Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced results from a preliminary preclinical proof of concept study of PAS002, its tolerizing vaccine for multiple sclerosis (MS).

Via Benzinga

Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders ↗

August 08, 2022

An estimated 200 million Americans — more than 60% of the population — suffer from at least one neurological disorder. That includes dementia, strokes, migraines and other diseases or infections that...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 02, 2022

Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA Sciences's trading volume reached 28.8 million shares. This is...

Via Benzinga

A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea ↗

July 28, 2022

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 22, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 20, 2022

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.

Via Benzinga

Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options ↗

July 20, 2022

Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing.

Via Benzinga

Pasithea Therapeutics Receives AUD $1 Million Research Award Following Recent Acquisition ↗

July 18, 2022

Pasithea Therapeutics Corp. (NASDAQ: KTTA) recently announced the availability of an AUD $1 million (USD $694,000) drug development research award following the Company's acquisition of Alpha-5...

Via Benzinga

This Biotech Company Says That It's Looking To Deliver A Breakthrough In Psychiatric Medicine — What's The Scoop? ↗

June 27, 2022

Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotech company with a goal of investigating novel drug treatments to provide more effective relief to the estimated 792 million people around the world...

Via Benzinga

EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition ↗

June 22, 2022

Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired Alpha-5 integrin LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for amyotrophic lateral sclerosis (ALS)...

Via Benzinga

Pasithea Biotech Reports That It's Aiming To Be At The Forefront Of The Mental Health Revolution ↗

April 25, 2022

Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Virtual Reality Technologies Are Reportedly Unlocking New Possibilities For Mental Healthcare ↗

April 18, 2022

Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Pasithea Reveals Cash Position Of $52.9 Million In Latest Earnings Report, To Expand Pipeline And Fund Operations Well Into 2024 ↗

April 01, 2022

Image sourced from Pixabay

Via Benzinga

This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction ↗

March 24, 2022

Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 17, 2022

On Tuesday, 123 stocks made new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 15, 2022

Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is...

Via Benzinga

Pasithea Partners With Glimpse Group To Co-Develop VR Environments For Patients With Psychiatric Disorders ↗

March 10, 2022

Photo by Maxim Hopman on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....

Via Benzinga

EXCLUSIVE: Glimpse-Pasithea To Co-Develop VR Environments For Patients With Psychiatric Disorders ↗

March 08, 2022

Pasithea Therapeutics Corp (NASDAQ: KTTA) has partnered with Glimpse Group Inc (NASDAQ: VRAR), a Virtual Reality and Augmented Reality (VR / AR) platform company, and its...

Via Benzinga

This Company Reports Using Ketamine To Treat Mental Health Disorders ↗

March 07, 2022

Photo by Sydney Sims on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice....

Via Benzinga

Pasithea To Open 3 New Clinics In The U.K. For Patients with Mental Health Issues, Each Clinic Expected To Add ~$5 Million In Annual Revenue ↗

February 25, 2022

Image by Christina on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Pasithea...

Via Benzinga

Pasithea Therapeutics Announces Plans To Open Three New Clinics In The UK By Mid-2022 ↗

February 24, 2022

-- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue -- -- New London locations will provide pharmacy services, ketamine therapy...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 03, 2022

Gainers Cidara Therapeutics (NASDAQ:CDTX)...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 03, 2022

Gainers SOC Telemed (NASDAQ:TLMD) shares increased by 338.2% to $2.82 during Thursday's pre-market session. The market value of their outstanding shares is at $284.5...

Via Benzinga

EXCLUSIVE: Pasithea Therapeutics Starts New Multiple Sclerosis Vaccine Development Program ↗

February 03, 2022

Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced a new chemical entity (NCE) development program and named Massachusetts-based Hooke Laboratories as its research partner.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.